Pharmacometabolomics of sulfonylureas in patients with type 2 diabetes: a cross-sectional study.

ABSTRACT:

Background

Sulfonylureas have been a longstanding pharmacotherapy in the management of type 2 diabetes, with potential benefits beyond glycemic control. Although sulfonylureas are effective, interindividual variability exists in drug response. Pharmacometabolomics is a potent method for elucidating variations in individual drug response. Identifying unique metabolites associated with treatment response can improve our ability to predict outcomes and optimize treatment strategies for individual patients. Our objective is to identify metabolic signatures associated with good and poor response to sulfonylureas, which could enhance our capability to anticipate treatment outcome.

Methods

In this cross-sectional study, clinical and metabolomics data for 137 patients with type 2 di

SUBMITTER: Naja K 

PROVIDER: S-EPMC11442225 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature